Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
1.750
-0.155 (-8.14%)
At close: Dec 20, 2024, 4:00 PM
1.890
+0.140 (8.00%)
After-hours: Dec 20, 2024, 7:27 PM EST
Dyadic International Revenue
Dyadic International had revenue of $1.96M in the quarter ending September 30, 2024, with 393.00% growth. This brings the company's revenue in the last twelve months to $3.36M, up 13.82% year-over-year. In the year 2023, Dyadic International had annual revenue of $2.90M, down -1.07%.
Revenue (ttm)
$3.36M
Revenue Growth
+13.82%
P/S Ratio
15.15
Revenue / Employee
$480,650
Employees
7
Market Cap
51.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.90M | -31.50K | -1.07% |
Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
Dec 31, 2019 | 1.68M | 385.63K | 29.77% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xtant Medical Holdings | 113.86M |
Spero Therapeutics | 106.46M |
SHL Telemedicine | 55.94M |
Celularity | 48.20M |
Cytosorbents | 37.74M |
DYAI News
- 4 weeks ago - Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology - GlobeNewsWire
- 5 weeks ago - Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - GlobeNewsWire
- 2 months ago - Dyadic Expands Global Presence with Participation in Key Industry Events - GlobeNewsWire
- 3 months ago - Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference - GlobeNewsWire
- 4 months ago - Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 - GlobeNewsWire
- 6 months ago - Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership - GlobeNewsWire